Indeed, certain targeted therapies could even be applied to multiple tumor types as seen in HDAC inhibitors for SHH-MB, MYC-amplified G3-MB, and DMG (52–55, 58–60, 137, 172). This evidence concerns the gene MYC and neoplasm.